<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627870</url>
  </required_header>
  <id_info>
    <org_study_id>ACOART intracranial ISR pilot</org_study_id>
    <nct_id>NCT04627870</nct_id>
  </id_info>
  <brief_title>ACOART Intracranial ISR Pilot:Intracranial DCB in the Treatment of Intracranial In-stent Restenosis</brief_title>
  <official_title>A Prospective, Multi-center, Randomized Controlled Trial to Evaluate the Safety and Feasibility of Intracranial Drug-coated Balloon Catheter in the Treatment of Intracranial In-stent Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acotec Scientific Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Acotec Scientific Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and feasibility of drug coated balloon in&#xD;
      treatment of intracranial in-stent restenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multi-center, randomized controlled trial using drug coated&#xD;
      balloon versus uncoated PTA balloon in treatment of intracranial in-stent restenosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target vessel stroke or death event</measure>
    <time_frame>within 30 days post-procedure</time_frame>
    <description>Target-vessel related stroke (bleeding and ischemia) or death within 30 days postoperatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success rate</measure>
    <time_frame>assessed during procedure</time_frame>
    <description>The balloon dilatation catheter was able to reach the treated lesion, successfully dilated without rupture, and successfully retreated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel ischemia stroke event</measure>
    <time_frame>between 31days and 12months post-procedure</time_frame>
    <description>The incidence of recurrent ischemic stroke in the target vessel supply area 31 days to 12 months after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral parenchyma hemorrhage, subarachnoid hemorrhage or intraventricular hemorrhage events</measure>
    <time_frame>between 31 days and 12 months post-procedure</time_frame>
    <description>Any cerebral parenchyma hemorrhage, subarachnoid hemorrhage, or intraventricular hemorrhage confirmed by MRI or CT from 31 days to 12 months post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target vessel death event</measure>
    <time_frame>between 31 days and 12 months post-procedure</time_frame>
    <description>Target-vessel related death 31 days to 12 months postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale score</measure>
    <time_frame>at 12 months post-procedure</time_frame>
    <description>National Institutes of Health Stroke Scale score at 12 months postoperatively(0-42, higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score score</measure>
    <time_frame>at 12 months post-procedure</time_frame>
    <description>Modified Rankin Score at 12 months postoperatively(0-5, higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Intracranial Atherosclerosis</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>DCB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use drug (paclitaxel) coated balloon to treat intracranial in-stent restenosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use PTA balloon to treat intracranial in-stent restenosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug (paclitaxel) coated balloon</intervention_name>
    <description>use drug (paclitaxel) coated balloon catheter to treat intracranial in-stent restenosis</description>
    <arm_group_label>DCB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTA balloon</intervention_name>
    <description>use traditional PTA balloon with NMPA approval of indication for treating intracranial stenosis</description>
    <arm_group_label>PTA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 80 years of age&#xD;
&#xD;
          -  Confirmed by DSA: in-stent restenosis (ISR) at intracranial segment of internal&#xD;
             carotid artery, middle cerebral artery, basilar artery and vertebral artery; ISR is&#xD;
             defined as &gt;50% stenosis within or immediately adjacent (within 5 mm) of the implanted&#xD;
             stent and &gt;20% absolute luminal loss&#xD;
&#xD;
          -  presence of ISR associated ischemic stroke or transient ischemic attacks even with&#xD;
             medical treatment and strict control of risk factor&#xD;
&#xD;
          -  asymptomatic ISR with severe hypoperfusion in the ISR territories, confirmed by a&#xD;
             cerebral blood flow decrease of ≥30% when compared with the perfusion on the&#xD;
             contralateral side for anterior circulation lesions or the anterior circulation&#xD;
             territory for posterior circulation lesions on CT perfusion, and/or by an American&#xD;
             Society of Interventional and Therapeutic Neuroradiology/Society of Interventional&#xD;
             Radiology (ASITN/SIR) Collateral Flow Grading System score &lt;3 on DSA.&#xD;
&#xD;
          -  the diameter of target vessel is 2.0-4.5mm&#xD;
&#xD;
          -  there is only one intracranial ISR lesion per subject&#xD;
&#xD;
          -  baseline mRS score ≤2&#xD;
&#xD;
          -  Voluntarily participate in this study and sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with stroke within 2 weeks before procedure;&#xD;
&#xD;
          -  any history of brain parenchyma or other intracranial subarachnoid, subdural or&#xD;
             extradural hemorrhage in the past 30 days.&#xD;
&#xD;
          -  Those who have received thrombolysis within 24 hours before procedure;&#xD;
&#xD;
          -  Deterioration of neurological function within 24 hours before procedure (defined as&#xD;
             NIHSS score increased by ≥ 4 points over the baseline)&#xD;
&#xD;
          -  patients with thrombus in target vessels.&#xD;
&#xD;
          -  in addition to ISR lesions, there are other primary intracranial lesions that need&#xD;
             endovascular treatment.&#xD;
&#xD;
          -  Major surgery (including open femoral, aortic or carotid artery surgery) is planned&#xD;
             within the past 30 days or within 90 days.&#xD;
&#xD;
          -  patients with renal artery, iliac artery and cardiac coronary artery requiring&#xD;
             simultaneous intervention.&#xD;
&#xD;
          -  Combined with intracranial tumors, aneurysms or intracranial arteriovenous&#xD;
             malformations.&#xD;
&#xD;
          -  Cardiac stroke or potential cardiogenic thromboembolism, with any of the following&#xD;
             cardiogenic embolism causes: chronic or paroxysmal atrial fibrillation, mitral valve&#xD;
             stenosis, mechanical valves, endocarditis, intracardiac thrombus or implant, dilated&#xD;
             cardiomyopathy, spontaneous acoustic imaging of the left atrium;&#xD;
&#xD;
          -  patients with myocardial infarction within 6 weeks before procedure.&#xD;
&#xD;
          -  those who cannot tolerate general anesthesia due to insufficiency of heart, lung and&#xD;
             other important organs.&#xD;
&#xD;
          -  patients with known severe hepatic and renal dysfunction.&#xD;
&#xD;
          -  patients with hemoglobin &lt; 100g / L, platelet count &lt; 100,000 / mm3, INR &gt; 1.5or with&#xD;
             uncorrectable factors leading to bleeding.&#xD;
&#xD;
          -  patients who cannot receive dual antiplatelet therapy due to existing diseases or who&#xD;
             are tested to be tolerant to dual antiplatelet therapy.&#xD;
&#xD;
          -  Patients with known severe allergies or contraindications to heparin, paclitaxel,&#xD;
             contrast agents and other related intravascular treatment drugs&#xD;
&#xD;
          -  current alcohol or drug abuse, uncontrolled severe hypertension (systolic blood&#xD;
             pressure &gt; 180mmHg or diastolic blood pressure &gt; 110mmHg).&#xD;
&#xD;
          -  Life expectancy &lt; 1 year.&#xD;
&#xD;
          -  pregnant or lactating women.&#xD;
&#xD;
          -  patients who are unable to complete follow-up due to cognitive, emotional disorders or&#xD;
             mental illness.&#xD;
&#xD;
          -  Patients who are participating in other drug/device clinical trials and have not&#xD;
             completed all follow-ups required by the programme;&#xD;
&#xD;
          -  According to the judgement of the investigator, other situations that are not suitable&#xD;
             for enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ning Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ning Ma, MD</last_name>
    <phone>13581889908</phone>
    <email>maning_03@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Ma, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intracranial Atherosclerosis</keyword>
  <keyword>In-stent restenosis</keyword>
  <keyword>drug coated balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

